Zacks Research Upgrades Keros Therapeutics (NASDAQ:KROS) to Strong-Buy

Keros Therapeutics (NASDAQ:KROS) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports.

A number of other analysts have also issued reports on the stock. Leerink Partners cut their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. Wall Street Zen upgraded shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Wells Fargo & Company cut their price objective on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Keros Therapeutics Trading Up 1.7%

Shares of Keros Therapeutics stock opened at $9.33 on Monday. The stock has a 50 day moving average of $11.11 and a 200 day moving average of $11.82. Keros Therapeutics has a fifty-two week low of $8.98 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Thursday, November 5th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $1.66. The company had revenue of $40.01 million for the quarter, compared to the consensus estimate of $14.76 million. Keros Therapeutics had a negative return on equity of 21.85% and a negative net margin of 256.60%. Research analysts predict that Keros Therapeutics will post -4.45 earnings per share for the current year.

Keros Therapeutics announced that its Board of Directors has approved a share buyback plan on Wednesday, September 9th that permits the company to buy back $5 million in shares. This repurchase authorization permits the company to reacquire up to 2.3% of its stock through open market purchases. Share repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the transaction, the insider directly owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This represents a 11.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,343 shares of company stock valued at $54,985 in the last 90 days. 12.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in KROS. Diversified Trust Co purchased a new position in Keros Therapeutics in the third quarter valued at approximately $133,000. Squarepoint Ops LLC purchased a new stake in shares of Keros Therapeutics during the 2nd quarter worth approximately $334,000. Hsbc Holdings PLC lifted its position in shares of Keros Therapeutics by 29.5% during the 2nd quarter. Hsbc Holdings PLC now owns 69,926 shares of the company’s stock worth $761,000 after buying an additional 15,940 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Keros Therapeutics in the 2nd quarter valued at $15,091,483. Finally, Empowered Funds LLC acquired a new position in shares of Keros Therapeutics in the 2nd quarter valued at $1,521,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics News Roundup

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target while raising its 2026 and 2027 earnings estimates. Separately, Zacks said KROS’s roughly 21% decline over four weeks had pushed it into oversold territory, which could leave room for a rebound if selling pressure eases. Zacks article
• Neutral Sentiment: A report listed short interest at zero shares and a zero-day short-interest ratio. The figure offers little indication of short-selling pressure, though it conflicts with the entry’s description of a large increase.
• Negative Sentiment: Keros is still forecast to report losses, and HC Wainwright trimmed its 2028–2030 earnings estimates. Those revisions point to ongoing uncertainty about the pace of the company’s path to profitability.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function. Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.